

Sagnik Bhattacharyya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6553397/publications.pdf>

Version: 2024-02-01

175
papers

9,757
citations

39113

52
h-index

46524

93
g-index

198
all docs

198
docs citations

198
times ranked

9327
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol. <i>Psychological Medicine</i> , 2022, 52, 2024-2031.	2.7	6
2	Cannabinoids, reward processing, and psychosis. <i>Psychopharmacology</i> , 2022, 239, 1157-1177.	1.5	12
3	Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 461-475.	1.8	11
4	Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence. <i>Brain Sciences</i> , 2022, 12, 101.	1.1	6
5	Cannabinoids in psychiatry: they are here to stay. <i>British Journal of Psychiatry</i> , 2022, , 1-3.	1.7	0
6	A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2022, 11, 324-332.	0.6	1
7	The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5616.	1.2	7
8	Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells. <i>Brain, Behavior, and Immunity</i> , 2022, 105, 82-97.	2.0	7
9	Cannabis use–related working memory deficit mediated by lower left hippocampal volume. <i>Addiction Biology</i> , 2021, 26, e12984.	1.4	5
10	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	2.7	7
11	Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. <i>Psychological Medicine</i> , 2021, 51, 596-606.	2.7	45
12	Hippocampal functional connectivity in Alzheimer’s disease: a resting state 7T fMRI study. <i>International Psychogeriatrics</i> , 2021, 33, 95-96.	0.6	4
13	Individualized prediction of 2-year risk of relapse as indexed by psychiatric hospitalization following psychosis onset: Model development in two first episode samples. <i>Schizophrenia Research</i> , 2021, 228, 483-492.	1.1	11
14	The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of Δ^9 -Tetrahydrocannabinol and Cannabidiol. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 636-645.	1.1	18
15	Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use. <i>Psychopharmacology</i> , 2021, 238, 1315-1331.	1.5	16
16	Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older. <i>JAMA Network Open</i> , 2021, 4, e2035913.	2.8	19
17	Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003524.	3.9	31
18	Mapping social reward and punishment processing in the human brain: A voxel-based meta-analysis of neuroimaging findings using the social incentive delay task. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 122, 1-17.	2.9	46

#	ARTICLE	IF	CITATIONS
19	Are researchers getting the terms used to denote different types of recreational cannabis right?â€”a user perspective. <i>Journal of Cannabis Research</i> , 2021, 3, 12.	1.5	1
20	Cannabidiol modulation of hippocampal glutamate in early psychosis. <i>Journal of Psychopharmacology</i> , 2021, 35, 814-822.	2.0	20
21	Eye movements in patients in early psychosis with and without a history of cannabis use. <i>NPJ Schizophrenia</i> , 2021, 7, 24.	2.0	1
22	Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. <i>Drugs and Aging</i> , 2021, 38, 887-910.	1.3	8
23	Epigenetic Mediation of AKT1 rs1130233â€™s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing. <i>Brain Sciences</i> , 2021, 11, 1240.	1.1	6
24	Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry. <i>Frontiers in Psychiatry</i> , 2021, 12, 771442.	1.3	0
25	Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. <i>Molecular Psychiatry</i> , 2020, 25, 3231-3240.	4.1	62
26	Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. <i>Psychological Medicine</i> , 2020, 50, 1862-1871.	2.7	13
27	Attentional bias towards cannabis cues in cannabis users: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107719.	1.6	14
28	Adolescentâ€™onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus. <i>Addiction Biology</i> , 2020, 25, e12827.	1.4	11
29	Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. <i>Psychopharmacology</i> , 2020, 237, 1121-1130.	1.5	60
30	Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence. <i>Frontiers in Psychiatry</i> , 2020, 11, 859.	1.3	47
31	Are adult stressful life events associated with psychotic relapse? A systematic review of 23 studies. <i>Psychological Medicine</i> , 2020, 50, 2302-2316.	2.7	34
32	T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION. <i>Schizophrenia Bulletin</i> , 2020, 46, S286-S286.	2.3	0
33	Cannabis: Neuropsychiatry and Its Effects on Brain and Behavior. <i>Brain Sciences</i> , 2020, 10, 834.	1.1	5
34	Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape. <i>Human Brain Mapping</i> , 2020, 41, 4386-4396.	1.9	9
35	Cannabis Use Linked to Altered Functional Connectivity of the Visual Attentional Connectivity in Patients With Psychosis and Controls. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	7
36	A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2020, 10, 311.	2.4	23

#	ARTICLE	IF	CITATIONS
37	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020, 11, 602480.	1.3	1
38	Is there sufficient evidence that cannabis use is a risk factor for psychosis?. , 2020, , 305-331.		8
39	The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study. <i>Schizophrenia Research</i> , 2020, 225, 63-68.	1.1	24
40	A Systematic Review of Human Neuroimaging Evidence of Memory-Related Functional Alterations Associated with Cannabis Use Complemented with Preclinical and Human Evidence of Memory Performance Alterations. <i>Brain Sciences</i> , 2020, 10, 102.	1.1	21
41	Î”9-tetrahydrocannabinol and 2-AG decreases neurite outgrowth and differentially affects ERK1/2 and Akt signaling in hiPSC-derived cortical neurons. <i>Molecular and Cellular Neurosciences</i> , 2020, 103, 103463.	1.0	24
42	Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. <i>Frontiers in Psychology</i> , 2020, 11, 833.	1.1	35
43	Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis. <i>Translational Psychiatry</i> , 2020, 10, 111.	2.4	3
44	Dysconnectivity of Large-Scale Functional Networks in Early Psychosis: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2019, 45, 579-590.	2.3	73
45	Cannabis and the Developing Brain: Insights into Its Long-Lasting Effects. <i>Journal of Neuroscience</i> , 2019, 39, 8250-8258.	1.7	124
46	Cannabidiol as a potential treatment for psychosis. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531988191.	1.2	74
47	O3.7. SMOOTH PURSUIT EYE MOVEMENTS INDICATE BIOLOGICAL DISTINCTION BETWEEN CANNABIS-USING AND NON-USING PATIENTS IN EARLY PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S167-S168.	2.3	1
48	O3.4. DOES CANNABIS INDUCE PSYCHOSIS BY ALTERING GLUTAMATE SIGNALING IN THE STRIATUM?. <i>Schizophrenia Bulletin</i> , 2019, 45, S166-S167.	2.3	0
49	O12.7. TREATMENT WITH CANNABIDIOL REDUCES RESTING STATE PERFUSION IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S200-S200.	2.3	1
50	Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2019, 9, 203.	2.4	47
51	Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. <i>Psychiatry Research</i> , 2019, 280, 112523.	1.7	13
52	Network organization of co-opetitive genetic influences on morphologies of the human cerebral cortex. <i>Journal of Neural Engineering</i> , 2019, 16, 026028.	1.8	1
53	Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans. <i>Brain Sciences</i> , 2019, 9, 93.	1.1	17
54	O3.1. ASSOCIATION OF EXTENT OF CANNABIS USE AND ACUTE INTOXICATION EXPERIENCES IN A MULTI-NATIONAL SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS. <i>Schizophrenia Bulletin</i> , 2019, 45, S165-S166.	2.3	0

#	ARTICLE	IF	CITATIONS
55	S170. Are Cannabis-Using and Non-Using Patients Different Groups? Evidence for Altered Volume Striatal Glutamate Relationships in Cannabis-Using Patients in Early Psychosis. <i>Biological Psychiatry</i> , 2019, 85, S363.	0.7	0
56	Regular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users: Results from a complementary meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 96, 45-55.	2.9	40
57	Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis. <i>Psychological Medicine</i> , 2019, 49, 103-112.	2.7	17
58	Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of Δ^9 -THC. <i>Psychological Medicine</i> , 2018, 48, 2748-2756.	2.7	11
59	Does thinner right entorhinal cortex underlie genetic liability to cannabis use?. <i>Psychological Medicine</i> , 2018, 48, 2766-2775.	2.7	11
60	17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S28-S28.	2.3	6
61	Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: findings from 40 years of follow-up. <i>Psychological Medicine</i> , 2018, 48, 2169-2176.	2.7	47
62	Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 623-630.	1.0	13
63	Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis". <i>Schizophrenia Bulletin</i> , 2018, 44, 18-19.	2.3	3
64	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 1-10.	1.5	17
65	17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS. <i>Schizophrenia Bulletin</i> , 2018, 44, S27-S27.	2.3	0
66	Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 825-849.	2.0	37
67	Residual effects of cannabis use in adolescent and adult brains " A meta-analysis of fMRI studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 88, 26-41.	2.9	69
68	The effects of cannabis use on salience attribution: a systematic review. <i>Acta Neuropsychiatrica</i> , 2018, 30, 43-57.	1.0	23
69	S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPIISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S384-S384.	2.3	3
70	The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task. <i>Neuropsychology Review</i> , 2018, 28, 496-506.	2.5	136
71	Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort. <i>Schizophrenia Bulletin</i> , 2018, 44, 1323-1331.	2.3	70
72	Neurocognitive effects of cannabis: Lessons learned from human experimental studies. <i>Progress in Brain Research</i> , 2018, 242, 179-216.	0.9	16

#	ARTICLE	IF	CITATIONS
73	Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 1107.	6.0	113
74	Driving Cessation in Patients Attending a Young-Onset Dementia Clinic: A Retrospective Cohort Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 190-198.	0.6	6
75	S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE. <i>Schizophrenia Bulletin</i> , 2018, 44, S413-S413.	2.3	0
76	O10.7. INVESTIGATING THE MECHANISMS UNDERLYING THE BENEFICIAL EFFECTS OF ESTROGENS IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S105-S105.	2.3	1
77	Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure. <i>European Neuropsychopharmacology</i> , 2018, 28, 850-862.	0.3	22
78	Cannabis use and the development of tolerance: a systematic review of human evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 93, 1-25.	2.9	101
79	T99. LONG-TERM CANNABIS USE ASSOCIATED WITH ALTERED FUNCTIONING DURING VERBAL LEARNING. <i>Schizophrenia Bulletin</i> , 2018, 44, S154-S154.	2.3	1
80	Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort. <i>Psychiatry Research</i> , 2018, 268, 381-387.	1.7	28
81	Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 582-598.	1.3	25
82	Do fewer males present to clinical high-risk services for psychosis relative to first-episode services?. <i>Microbial Biotechnology</i> , 2017, 11, 429-435.	0.9	6
83	Do cognitive schema mediate the association between childhood trauma and being at ultra-high risk for psychosis?. <i>Journal of Psychiatric Research</i> , 2017, 88, 89-96.	1.5	53
84	Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017, 47, 1691-1705.	2.7	53
85	Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis. <i>Psychiatry Research</i> , 2017, 255, 36-41.	1.7	19
86	Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. <i>Current Addiction Reports</i> , 2017, 4, 62-74.	1.6	115
87	288. Δ^9 -THC Modulates Fear Processing and Functional Connectivity in an Emotional Salience Task. <i>Biological Psychiatry</i> , 2017, 81, S118-S119.	0.7	0
88	Is there a "critical age" for first use of marijuana? Analysis of cannabis induced experiences by age at first use in a large internet-based sample. <i>European Psychiatry</i> , 2017, 41, s835-s836.	0.1	0
89	Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. <i>Scientific Reports</i> , 2017, 7, 15025.	1.6	57
90	Early psychosis for the non-specialist doctor. <i>BMJ: British Medical Journal</i> , 2017, 357, j4578.	2.4	9

#	ARTICLE	IF	CITATIONS
91	How to approach psychotic symptoms in a non-specialist setting. <i>BMJ: British Medical Journal</i> , 2017, 359, j4752.	2.4	2
92	Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. <i>Lancet Psychiatry</i> , 2017, 4, 627-633.	3.7	93
93	Can cognitive insight predict symptom remission in a first episode psychosis cohort?. <i>BMC Psychiatry</i> , 2017, 17, 54.	1.1	29
94	Neuroimaging and Genetics of the Acute and Chronic Effects of Cannabis. , 2017, , e42-e52.		1
95	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw181.	2.3	44
96	SU71. Effects of Cannabidiol on Mediotemporal and Dorsostriatal Activity During Encoding and Recall, in the At-Risk Mental State for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, S187-S187.	2.3	2
97	Investigating the Role of the Endocannabinoid System in Early Psychosis. <i>Journal of Exploratory Research in Pharmacology</i> , 2017, 2, 85-92.	0.2	1
98	Adversity in childhood linked to elevated striatal dopamine function in adulthood. <i>Schizophrenia Research</i> , 2016, 176, 171-176.	1.1	77
99	The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. <i>Psychological Medicine</i> , 2016, 46, 177-188.	2.7	72
100	Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. <i>BMJ Open</i> , 2016, 6, e009888.	0.8	109
101	Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. <i>Psychological Medicine</i> , 2016, 46, 27-45.	2.7	32
102	Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2016, 73, 1173.	6.0	71
103	Continuity of cannabis use and violent offending over the life course. <i>Psychological Medicine</i> , 2016, 46, 1663-1677.	2.7	48
104	Impact of childhood trauma on risk of relapse requiring psychiatric hospital admission for psychosis. <i>British Journal of Psychiatry</i> , 2016, 209, 169-170.	1.7	11
105	Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. <i>Lancet Psychiatry</i> , 2016, 3, 947-953.	3.7	120
106	Correlation still does not imply causation – Authors' reply. <i>Lancet Psychiatry</i> , 2016, 3, 401-402.	3.7	5
107	Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2016, 3, 215-225.	3.7	229
108	Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2016, 173, 392-399.	4.0	104

#	ARTICLE	IF	CITATIONS
109	Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 64, 359-381.	2.9	117
110	Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. <i>Journal of Psychopharmacology</i> , 2016, 30, 99-111.	2.0	21
111	Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. <i>European Neuropsychopharmacology</i> , 2015, 25, 26-37.	0.3	68
112	Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. <i>Lancet, The</i> , 2015, 385, S79.	6.3	23
113	Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. <i>European Neuropsychopharmacology</i> , 2015, 25, 1201-1224.	0.3	53
114	A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. <i>Psychiatry Research</i> , 2015, 225, 14-30.	1.7	181
115	Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience. <i>Neuropsychopharmacology</i> , 2015, 40, 1343-1352.	2.8	101
116	Editorial (Thematic Issue: Neurobiological and Neurocognitive Basis of the Effects of Cannabinoids in) <i>Tj ETQq0 0 0 rgBT /Overlock 10 TF Design</i> , 2014, 20, 2069-2071.	0.9	2
117	Protein kinase B (<i>AKT1</i>) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. <i>Psychological Medicine</i> , 2014, 44, 3315-3328.	2.7	36
118	Modulation of brain structure by catecholâ€œmethyltransferase <i>Val¹⁵⁸Met</i> polymorphism in chronic cannabis users. <i>Addiction Biology</i> , 2014, 19, 722-732.	1.4	34
119	Cannabis use and transition to psychosis in people at ultra-high risk. <i>Psychological Medicine</i> , 2014, 44, 2503-2512.	2.7	83
120	Road work on memory laneâ€œFunctional and structural alterations to the learning and memory circuit in adults born very preterm. <i>NeuroImage</i> , 2014, 102, 152-161.	2.1	38
121	Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or Δ^9 -tetrahydrocannabinol (THC). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 52, 53-69.	2.5	56
122	Neural compensation in adulthood following very preterm birth demonstrated during a visual paired associates learning task. <i>NeuroImage: Clinical</i> , 2014, 6, 54-63.	1.4	15
123	P.3.b.024 Effect of childhood adversity on brain dopamine function in adulthood. <i>European Neuropsychopharmacology</i> , 2014, 24, S505.	0.3	0
124	Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 2168-2185.	0.9	56
125	Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 2218-2230.	0.9	33
126	Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies. <i>Current Pharmaceutical Design</i> , 2014, 20, 2114-2125.	0.9	68

#	ARTICLE	IF	CITATIONS
127	Presynaptic Striatal Dopamine Dysfunction in People at Ultra-high Risk for Psychosis: Findings in a Second Cohort. <i>Biological Psychiatry</i> , 2013, 74, 106-112.	0.7	208
128	Dhat Syndrome: A Systematic Review. <i>Psychosomatics</i> , 2013, 54, 212-218.	2.5	34
129	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ^9 -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. <i>Psychological Medicine</i> , 2013, 43, 1255-1267.	2.7	51
130	The effect of cannabis use on memory function: an update. <i>Substance Abuse and Rehabilitation</i> , 2013, 4, 11.	1.6	56
131	Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings. <i>PLoS ONE</i> , 2013, 8, e55821.	1.1	334
132	A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation. <i>Current Pharmaceutical Design</i> , 2012, 18, 5131-5140.	0.9	174
133	Induction of Psychosis by Δ^9 -Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Saliency Processing. <i>Archives of General Psychiatry</i> , 2012, 69, 27.	13.8	193
134	Acute Effects of a Single, Oral dose of Δ^9 -tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers. <i>Current Pharmaceutical Design</i> , 2012, 18, 4966-4979.	0.9	225
135	Communication breakdown: Δ^9 tetrahydrocannabinol effects on pre-speech neural coherence. <i>Molecular Psychiatry</i> , 2012, 17, 568-569.	4.1	18
136	Interpersonal sensitivity in the at-risk mental state for psychosis. <i>Psychological Medicine</i> , 2012, 42, 1835-1845.	2.7	63
137	Alterations in White Matter Evident Before the Onset of Psychosis. <i>Schizophrenia Bulletin</i> , 2012, 38, 1170-1179.	2.3	186
138	Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of Δ^9 -tetrahydrocannabinol on midbrain and striatal function. <i>Molecular Psychiatry</i> , 2012, 17, 1152-1155.	4.1	108
139	Substance use and regional gray matter volume in individuals at high risk of psychosis. <i>European Neuropsychopharmacology</i> , 2012, 22, 114-122.	0.3	21
140	Effect of BDNF val66met polymorphism on declarative memory and its neural substrate: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 2165-2177.	2.9	125
141	Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man: A Critical Review of Neuroimaging Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 5045-5054.	0.9	58
142	CANNABIS, CNS RHYTHMS & POSITIVE PSYCHOTIC SYMPTOMS. <i>Schizophrenia Research</i> , 2012, 136, S25-S26.	1.1	0
143	Neuroimaging Evidence for Cannabinoid Modulation of Cognition and Affect in Man. <i>Frontiers in Behavioral Neuroscience</i> , 2012, 6, 22.	1.0	6
144	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>Journal of Psychopharmacology</i> , 2011, 25, 121-130.	2.0	406

#	ARTICLE	IF	CITATIONS
145	Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis. <i>Biological Psychiatry</i> , 2011, 69, 97-99.	0.7	59
146	Disruption of Frontal Theta Coherence by δ^9 -Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. <i>Neuropsychopharmacology</i> , 2011, 36, 827-836.	2.8	74
147	Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study. <i>Neuropsychopharmacology</i> , 2011, 36, 1340-1348.	2.8	126
148	Neuroimaging in cannabis use: a systematic review of the literature. <i>Psychological Medicine</i> , 2010, 40, 383-398.	2.7	189
149	Delta-9-Tetrahydrocannabinol Disruption of Time Perception and of Self-Timed Actions. <i>Pharmacopsychiatry</i> , 2010, 43, 236-237.	1.7	11
150	ALTERED MEDIAL TEMPORAL ACTIVATION RELATED TO LOCAL GLUTAMATE IN SUBJECTS WITH PRODROMAL SIGNS OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 533.	1.1	1
151	Effect of image analysis software on neurofunctional activation during processing of emotional human faces. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 311-314.	0.8	23
152	Modulation of effective connectivity during emotional processing by δ^9 -tetrahydrocannabinol and cannabidiol. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 421.	1.0	134
153	Opposite Effects of δ^9 -Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. <i>Neuropsychopharmacology</i> , 2010, 35, 764-774.	2.8	595
154	Distinct Effects of δ^9 -Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. <i>Archives of General Psychiatry</i> , 2009, 66, 95.	13.8	412
155	Modulation of Mediotemporal and Ventrostriatal Function in Humans by δ^9 -Tetrahydrocannabinol. <i>Archives of General Psychiatry</i> , 2009, 66, 442.	13.8	226
156	Cannabis and anxiety: a critical review of the evidence. <i>Human Psychopharmacology</i> , 2009, 24, 515-523.	0.7	398
157	Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume. <i>Biological Psychiatry</i> , 2009, 66, 533-539.	0.7	210
158	Opposite Neural Effects of the Main Psychoactive Ingredients of Cannabis- Neural Basis for Potential Therapeutic Effects of Cannabidiol. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
159	P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis – implications for therapeutics. <i>European Neuropsychopharmacology</i> , 2009, 19, S63-S64.	0.3	1
160	Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive-Compulsive Disorder. <i>Neuropsychopharmacology</i> , 2009, 34, 2489-2496.	2.8	139
161	Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology. <i>Current Pharmaceutical Design</i> , 2009, 15, 2603-2614.	0.9	50
162	Neural Basis of δ^9 -Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition. <i>Biological Psychiatry</i> , 2008, 64, 966-973.	0.7	179

#	ARTICLE	IF	CITATIONS
163	P.3.21 Delta-9-tetrahydrocannabinol modulates activity in parahippocampal cortex and ventral striatum during memory processing. <i>European Neuropsychopharmacology</i> , 2008, 18, s80.	0.3	0
164	P.1.e.020 Effects of cannabis ingredients in the temporal cortex – neural basis for potential antipsychotic effect of cannabidiol. <i>European Neuropsychopharmacology</i> , 2008, 18, S270-S271.	0.3	0
165	P.2.05 Acute cannabinoid effects on brain activation during response inhibition. <i>European Neuropsychopharmacology</i> , 2007, 17, S43-S44.	0.3	0
166	Glutamatergic Dysfunction-Newer Targets for Anti-Obsessional Drugs. <i>Recent Patents on CNS Drug Discovery</i> , 2007, 2, 47-55.	0.9	35
167	Anti-depressive Therapies After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 785-793.	0.3	35
168	A family genetic study of clinical subtypes of obsessive-compulsive disorder. <i>Psychiatric Genetics</i> , 2005, 15, 175-180.	0.6	10
169	Depressive and Anxiety Disorder Comorbidity in Obsessive Compulsive Disorder. <i>Psychopathology</i> , 2005, 38, 315-319.	1.1	15
170	Glutamatergic Dysfunction in OCD. <i>Neuropsychopharmacology</i> , 2005, 30, 1735-1740.	2.8	322
171	Late onset OCD. <i>Australian and New Zealand Journal of Psychiatry</i> , 2004, 38, 477-478.	1.3	11
172	Early-Onset Obsessive-Compulsive Disorder. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 352-353.	0.9	0
173	Metamorphosis of Delusion of Pregnancy. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 561-562.	0.9	12
174	The neural basis for the acute effects of cannabis on learning and psychosis. , 0, , 160-168.		1
175	Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis. <i>Psychological Medicine</i> , 0, , 1-10.	2.7	2